Compare SYNA & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SYNA | ADPT |
|---|---|---|
| Founded | 1986 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.3B |
| IPO Year | 2001 | 2019 |
| Metric | SYNA | ADPT |
|---|---|---|
| Price | $131.55 | $13.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $100.78 | $17.78 |
| AVG Volume (30 Days) | 890.8K | ★ 1.5M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $663,588,000.00 | $276,976,000.00 |
| Revenue This Year | $12.63 | $3.98 |
| Revenue Next Year | $9.67 | $22.72 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 21.04 | ★ 54.77 |
| 52 Week Low | $57.54 | $8.50 |
| 52 Week High | $129.78 | $20.76 |
| Indicator | SYNA | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 77.95 | 41.50 |
| Support Level | $63.44 | $12.22 |
| Resistance Level | N/A | $13.45 |
| Average True Range (ATR) | 7.70 | 0.75 |
| MACD | 3.48 | -0.09 |
| Stochastic Oscillator | 93.50 | 5.20 |
Synaptics Inc is a producer of semiconductor solutions for the mobile, PC, and Internet of Things markets. The company develops human interface solutions that enable touch, display, fingerprint, video, audio, voice, AI, and connectivity functions for smartphones, PCs, Internet of Things products, and other electronic devices. It operates in one segment: the development, marketing, and sale of semiconductor products used in electronic devices and products. The company geographically, it derives a majority of revenue from China, and also has its presence in Taiwan, Japan, South Korea, United States and Other countries.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.